SCHEMBL1240693

SCHEMBL1240693

CCCOc1ccc(CCO)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.64
L3MBTL1 Q9Y468 2/20 0.64
ALDH1A1 P00352 4/20 0.57
KMT2A Q03164 3/20 0.57
MAPK1 P28482 2/20 0.57
MEN1 O00255 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
USP2 O75604 1/20 0.57
CYP3A4 P08684 1/20 0.57
CASP1 P29466 1/20 0.57
SLCO1B3 Q9NPD5 1/20 0.57
SLCO1B1 Q9Y6L6 1/20 0.57
LTA4H P09960 1/20 0.53
HRH3 Q9Y5N1 1/20 0.53
ACACB O00763 1/20 0.51
SLC5A1 P13866 1/20 0.51
SLC5A2 P31639 1/20 0.51
SPHK2 Q9NRA0 1/20 0.51
SPHK1 Q9NYA1 1/20 0.51
CYP1A2 P05177 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7837295 0.92 ALDH1A1 (0.66) LMNAL3MBTL1ALDH1A1KMT2AMAPK1
SCHEMBL7216854 0.89 ALDH1A1 (0.62) LMNAL3MBTL1ALDH1A1KMT2AMAPK1
SCHEMBL9471180 0.89 MEN1 (0.67) LMNAALDH1A1KMT2AMAPK1MEN1
SCHEMBL6658231 0.87 HRH3 (0.59) LMNAL3MBTL1ALDH1A1KMT2AMAPK1
SCHEMBL8500363 0.87 MEN1 (0.69) LMNAALDH1A1KMT2AMAPK1MEN1
SCHEMBL7623214 0.87 MEN1 (0.69) LMNAALDH1A1KMT2AMAPK1MEN1
SCHEMBL1667156 0.87 MEN1 (0.69) LMNAALDH1A1KMT2AMAPK1MEN1
SCHEMBL12559687 0.87 MEN1 (0.69) LMNAALDH1A1KMT2AMAPK1MEN1
SCHEMBL8498228 0.87 MEN1 (0.69) LMNAALDH1A1KMT2AMAPK1MEN1
SCHEMBL10427155 0.87 MEN1 (0.69) LMNAALDH1A1KMT2AMAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115210239-B Aromatic compound, organic semiconductor layer, and organic thin film transistor 东曹株式会社 2025-04-11 CN disclosed
US-20230142592-A1 AROMATIC COMPOUND, ORGANIC SEMICONDUCTOR LAYER AND ORGANIC THIN FILM TRANSISTOR TOSOH CORPORATION (JP) 2023-05-11 US disclosed
CN-115210239-A Aromatic compound, organic semiconductor layer and organic thin film transistor 东曹株式会社 2022-10-18 CN disclosed
US-20180057953-A1 PLATING SOLUTION USING AMMONIUM SALT MITSUBISHI MATERIALS CORPORATION (JP) 2018-03-01 US disclosed
US-20180051383-A1 PLATING SOLUTION USING PHOSPHONIUM SALT MITSUBISHI MATERIALS CORPORATION (JP) 2018-02-22 US disclosed
US-20180051384-A1 PLATING SOLUTION USING SULFONIUM SALT MITSUBISHI MATERIALS CORPORATION (JP) 2018-02-22 US disclosed
US-8586614-B2 Urea glucokinase activators NOVO NORDISK A/S (DK) 2013-11-19 US disclosed
CN-101263131-B Urea glucokinase activators TRANSTECH PHARMA INC 2013-04-24 CN disclosed
EP-2377856-A1 Urea glucokinase activators NOVO NORDISK A/S (DK) 2011-10-19 EP disclosed
US-20110077234-A1 Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2011-03-31 US disclosed
US-7884210-B2 {2-[3-(2-Cyclohex-1-enyl-ethyl)-3-(trans-4-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; for treatment of type 2 diabetes NOVO NORDISK A/S (DK) 2011-02-08 US disclosed
US-20090105482-A1 Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2009-04-23 US disclosed
CN-101263131-A Urea glucokinase activators NOVO NORDISK AS (US) 2008-09-10 CN disclosed
EP-1904467-A1 UREA GLUCOKINASE ACTIVATORS Novo Nordisk A/S (DK) 2008-04-02 EP disclosed
WO-2007006814-A1 UREA GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2007-01-18 WO disclosed
US-6627651-B1 Exhibiting preventive and therapeutic effects against HIV infectious diseases wherein R1 is an optionally substituted five- or six-membered ring group; X1 is a free valency or the like; W is a divalent group and inhibitors of HIV (human TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-09-30 US disclosed
EP-1182195-A1 CYCLIC COMPOUNDS AND USES THEREOF Takeda Chemical Industries, Ltd. (JP) 2002-02-27 EP disclosed
US-6106999-A SENSITIVITY TO GENERAL-PURPOSE VISIBLE LIGHT LASER, SO THAT HIGH-SPEED SCANNING EXPOSURE IS POSSIBLE BY LASER, AND EXTREMELY FINE HIGH RESOLUTION CAN BE OBTAINED; CAN BE USED FOR COATING OR PRINTING UNDER SAFELIGHT IRRADIATING CONDITIONS MITSUI CHEMICALS (JP) 2000-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230142592-A1 AROMATIC COMPOUND, ORGANIC SEMICONDUCTOR LAYER AND ORGANIC THIN FILM TRANSISTOR CHRM1, CHRM2, ACVRL1 LMNA 2850/4885L3MBTL1 452/4885ALDH1A1 1807/4885
US-20090105482-A1 Urea Glucokinase Activators GCK, GCKR, HK2 LMNA 3732/4885L3MBTL1 3946/4885ALDH1A1 1040/4885
US-20110077234-A1 Urea Glucokinase Activators GCK, GCKR, HK2 LMNA 3732/4885L3MBTL1 3946/4885ALDH1A1 1040/4885
US-20180051383-A1 PLATING SOLUTION USING PHOSPHONIUM SALT PPM1F, PPM1A, PSPH LMNA 4113/4885L3MBTL1 2697/4885ALDH1A1 3065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.